Emerging Medtech Markets Vivo Ventures Time Arrives As All Eyes Look To China
|
|
- Peregrine O’Connor’
- 8 years ago
- Views:
Transcription
1 Special Reprint Elsevier Business Intelligence Emerging Pharma Markets Ironwood Adds A China Wrinkle To Regional Deal Strategy By Wendy Diller Emerging Medtech Markets Vivo Ventures Time Arrives As All Eyes Look To China By Tom Salemi DECEMBER 212 Vol. 3, No. 11 Biopharma Dealmaking Pharma Deals That Generate Lasting Value: A Roundtable Discussion By Christopher Morrison Medtech Business Strategies Innovation & Globalization In Medtech: An Interview With Medtronic s Omar Ishrak Building on the triple pillars of execution, globalization, and innovation, Omar Ishrak is positioning Medtronic for a new medical device marketplace. by DAVID CASSAK Also in this issue: Too Big To Succeed: Where Are Large Pharmas Heading? Renal Denervation Land Grab Continues Molecular Diagnostics M&A: Dormant But Not Done
2 TOO BIG TO SUCCEED: WHERE ARE LARGE PHARMAS HEADING? The biopharmaceutical industry s largest companies have grown too large to offer shareholders a compelling return. Historically focused on strategic adaptations to the market environment, large pharmas now need to address key internal issues such as scale as a core foundation of their growth aspirations. n Over the past 25 years, large pharmaceutical companies have scaled up operations to increase market share, competitive positioning, and global presence. But R&D productivity at industry s largest companies has declined significantly. n In fact, L.E.K. Consulting analysis shows that total sales and market cap of pharma companies are negative predictors of total shareholder returns. A pipeline productivity analysis also highlights that the number of product approvals required to achieve sufficient growth targets for large pharmas is most likely unachievable. n To address these challenges, large pharmas may further consolidate to externally fill pipeline gaps, diversify beyond pharmaceuticals to access adjacent profit segments, deconsolidate, or restructure around a smaller revenue base of high value therapeutic areas. n understanding the key challenges of scale and applying the learnings from this analysis will enable large pharma executives to sustain growth and maximize shareholder value creation. Executive Summary >> 98 BY David Barrow, Matthias Kleinz, Michael Gladstone, and Pierre Jacquet Diminishing R&D productivity, patent cliffs, pricing pressures, and tougher regulations have contributed to decelerated growth in the pharmaceutical industry. These challenges have forced large pharmas, defined throughout this analysis as the top 1 global pharmaceutical companies by 211 revenue, to rethink their business models. (See Exhibit 1.) Among these changes have been the evolution of pharmaceutical commercial models toward new customers (e.g., payors), increased externalization of R&D through consolidation and dealmaking, reorganization into smaller business units for increased productivity, and geographic expansion to access faster-growing emerging markets. But none of these fixes, all incrementally positive, addresses the fundamental dilemma facing large pharmas. L.E.K. findings indicate that company scale is a negative predictor of value creation among biopharmaceutical companies. And industry s largest companies have simply become too large to generate significant shareholder return going forward. Total shareholder return (TSR), calculated by combining share price appreciation with dividends yield during a period of time, has been inversely correlated to the revenue scale as well as to the market capitalization of pharma companies. (See Exhibit 2.) At the same time, sales growth has been the strongest predictor of positive TSR, which has been most often achieved by innovative companies off a smaller revenue base. Hence, the larger a company is, the more difficult it is to grow and generate positive TSR. Scale As Impediment To Growth Though the pharmaceutical industry recognizes that the health care ecosystem is irreversibly changing, and is beginning to grapple with the market access and reimbursement challenges that will be core to any future success, there are more difficult times ahead. As health care costs relative to GDP spending continue to rise in major markets, pressures on large pharma companies to demonstrate the value of their products will continue to increase. Furthermore, major classes of innovative molecules are still going generic, shaving off another $12 billion in branded revenues in the next five years and offering payors more choice for lower cost options, increasing the hurdle for the subsequent generation of therapies to demonstrate value. Lastly, while emerging markets will remain a major contributor to spending growth for pharmaceuticals over the next five years, their contribution will still be steered by generics as substantial out-of-pocket costs of brands and expensive newer medicines will dampen branded pharmaceuticals revenue growth in these markets. In this environment, large pharmas will continue to struggle for value creation. 2 December 212 IN VIVO: The Business & Medicine Report
3 Exhibit 1 Top Ten Pharma Companies By 211 Revenue 211 Pharma Revenue ($B) Company Pfizer 67.4 Johnson & Johnson 65. Novartis 58.6 Merck & Co. 48. Roche 47.9 Sanofi 46.5 GlaxoSmithKline 43.9 Abbott Laboratories 38.9 AstraZeneca 33.6 Eli Lilly 24.3 SOURCE: Company Reports Indeed, large pharmas consistently trailed broader market indices over the past decade and underperformed the S&P5 by more than 2%. (See Exhibit 3.) In contrast, mid-tier biopharma companies, defined as the next 2 biopharma companies by revenue size, outperformed most indices during the same period. A recent annual audit of the pharmaceutical industry by St. Joseph s University s Bill Trombetta, PhD, published in Pharmaceutical Executive confirmed this trend. The five best performing companies in 211 as measured against eight financial metrics were mid-size companies such as Biogen Idec Inc., Shire PLC, Novo Nordisk AS, Celgene Corp. and Bristol- Myers Squibb Co. Interestingly, none of the top ten pharmaceutical companies by 211 sales came close to this group of outperformers. This issue of scale will become more pronounced in the near future. Looking at the past decade, the scale and revenue base at which large pharmas grew has more than doubled. Today, a top 1 pharma generates average global revenue of $47 billion, including nonpharmaceutical revenues for companies like Johnson & Johnson, Novartis AG, and Roche. Market leaders such as Pfizer Inc. have today a revenue base close to $7 billion in a global pharmaceutical market that is just over ten times that size. It may take only five to seven years before we see the first large pharma with a revenue base in excess of $1 billion, a timeline that can be accelerated if further consolidation takes place. This increase in scale and revenue base for growth has become one of the major challenges for large pharmas to create shareholder value in an environment increasingly constrained by static or declining performance on drivers such as the productivity of organic R&D. Understanding the key challenges of scale and applying the learnings from this analysis will enable large pharma executives to consider scale so their business models evolve to sustain growth and maximize shareholder value creation. The Burden Of Scale Scale can be a competitive advantage when considering the lifecycle of a portfolio of pharmaceutical drugs, with its flow of new product launches. With 1-12 years of patent life typically left after market entry, size and speed to global peak sales have become increasingly important. Leveraging the global scale of clinical, regulatory, market access, and commercial capabilities can accelerate revenue and earnings growth by fostering synergies across a portfolio of products, accessing networks of key stakeholders across geographies, and accelerating timeline of launch and ramp-up to peak. (See The Value of Scale in Pharma s Future IN VIVO, September 21.) Scale also enables large pharmas to enter high cost-of-entry markets. These include the therapeutic interventions that require expensive primary care promotion as well as expansion into geographies like China that requires significant investments to address underdeveloped infrastructure and fragmented distribution systems. Lastly, there is growing evidence that scale may improve share of voice for large pharmas in their negotiations with payors for formulary status of their drug portfolios. However, scale also introduces its own challenges. R&D productivity is one area where scale has not enabled improvement. In truth, it may be counterproductive. A recent analysis of the R&D spend by Big Pharma (albeit not the exact cohort of companies used for this analysis) highlighted negative returns over the past decade as the share of drugs originated from those companies declined to barely a quarter of the industry pipeline, down from nearly 4% in 2. (See Pharma R&D: Doing the Same Thing That Didn t Work Before IN VIVO, April 29.) Although scale can enhance efficiency of R&D processes that are repeatable and can be industrialized, such as highthroughput gene sequencing or combinatorial chemistry in early discovery stage, these positive effects do not systematically apply to more complex R&D activities such as the design and completion of small proof-of-concept clinical trials. When companies are small, decision makers are able to make strategic choices Exhibit 2 Drivers Of Total Shareholder Return For Leading Pharma Companies (25-21)** TSR% Market Captialization 25 ($B) *Historical datasets are less complete over the period due to mergers and acquisitions, resulting in weaker statistical significance; **Includes data for 42 of the 5 leading pharma companies by sales in 21; from multiple regression. SOURCE: S&P Capital IQ; L.E.K. analysis 2 TSR% Total Company Sales 25 ($B) Windhover Information Inc., an Elsevier company IN VIVO: The Business & Medicine Report December 212 3
4 Exhibit 3 Large Pharma And Mid-Tier Pharma Performance (21-211) Percent Large Pharmas S&P 5 Mid-Tier Pharmas SOURCE: S&P CapitaI IQ; L.E.K. Consulting Exhibit 4 Need For New Product Launches To Sustain Target Growth Rate By Company Size SOURCE: L.E.K. Consulting NDAs/BLAs Over Next 1 Years Required To Attain Growth Target Base Revenue $6B $4B 14 $2B Annual % Sales Growth Target in a swift and flexible manner without getting caught in exhaustive processes. As size increases, the hindered knowledge flow and the addition of stakeholders call for increasingly analytical, organized, and time-consuming R&D procedures. Over time these discourage risk-taking, rewarding consensus-building over bold decision-making. To better illustrate this counterproductive effect of scale and R&D productivity one must look at the number of NDAs/ BLAs required for sustaining a targeted corporate revenue growth rate. (See Exhibit 4.) Accounting for an average revenue decay due to expiring patents, a mid-tier pharma company with a revenue base of $2 billion and an annual revenue growth rate target of 1% for the next decade would need to generate about 3 to 4 NDAs/BLAs with average peak global sales of $1 billion to meet the goal during that period. This R&D productivity requirement translates into three to four NDAs/BLAs per year, a goal that can be theoretically achieved given the current average flow of 3-4 annual FDA approvals, though admittedly one that very few companies are likely to achieve. Scaling up these numbers for a large pharma with a revenue base of $4 billion with the same revenue growth aspirations implies an even loftier productivity requirement, about six to eight NDAs/ BLAs per year. This estimate is even more confounding for a large pharma with a revenue base of $6 billion, bringing this requisite to 1-12 NDAs/BLAs per year to meet this growth target. For companies of this scale, achieving such high productivity is likely unattainable. Indeed, there have been about 3 total NDAs and BLAs approved over the past decade, and over the past three years not a single large pharma has accounted for more than 1% of approvals in a given year, well below the implied approval share of 2%-3% for a single large pharma with a revenue base of $4 to $6 billion. Heightening this productivity requirement is the shifting nature of drugs emerging from large pharmas pipelines. There is growing evidence that blockbuster drugs, defined as those with more than $1 billion in annual sales, may account for a smaller share of large pharma revenues in the near future. (See The New Face Of Blockbuster Drugs IN VIVO, May 211.) If this scenario holds true, the requisite productivity for large pharmas will balloon to levels never achieved before. In any case, the current scale of large pharmas has stretched R&D output requirement to untenable goals and suggests that large pharma growth expectations will not be achievable for the system as a whole, although there may be wide variation among individual companies. Keep Consolidating In light of these challenges, an obvious path to fill this organic R&D gap is asset externalization. (See Institutionalizing Externalization At Big Pharma The Third Leg IN VIVO, March 212.) The ground for such a strategic move has been fertile over the past decade as drugs initially discovered in biotechnology companies or universities accounted for more than half of the scientifically innovative drugs approved during that time. However, as much as relying on a few good licensing and M&A deals with these innovators was impacting growth for large pharmas a decade ago, mirroring the effect of this approach on current large pharma scale can only happen under two conditions. The first relies on a pool of external innovation expanding at a faster rate than large pharma growth targets. The second presumes that the consolidation process of integrating these assets within the wall of large pharmas does not exacerbate the challenges of scale in these organizations. 4 December 212 IN VIVO: The Business & Medicine Report
5 These conditions appear highly unlikely to hold true. When looking at the biopharma industry composition, one may see a contraction of the pool of external innovation available for large pharmas. First, at a private company level, investment has slowed. Venture capitalists invested $5.6 billion last year in comparison to $4.2 billion invested five years ago, according to data from CapIQ and BioCentury. Adjusting this figure for inflation during the same period results in anemic expansion of private financing for innovation. For publically traded biotech companies, the numbers do not look better. There were about 49 biotech companies in this group a decade ago. Today this number has only ramped to about 55 companies. Within this group, the number of companies with a market cap of more than half a billion dollars has shrunk by almost 2% during the same period. Furthermore, the mid-tier biotech group, defined as companies with a market cap of $2 billion to $2 billion, has been depleted through mergers and acquisitions. These companies have traditionally offered solid growth foundations for large pharmas as most bring either top-line revenue from a marketed product or equity appreciation from a late-stage asset. A decade ago, 112 companies were traded in this pool. Today, only 55 remain, while the pool has been only partially replenished by 37 new companies. (See Exhibit 5.) Large pharmas have acquired more than 5% of those companies. Worse, this pool is being replenished at a pace too slow to meet large pharmas revenue growth ambitions. These dynamics signal a looming gap between an increasing reliance of large pharmas on external R&D and a shortage of the innovation supply from smaller to mid-scale companies. At a larger scale, consolidation has also not solved large pharma growth challenges. Recent large pharma M&A activities had the unintended effects of magnifying the constraints of scale for these companies and further aggravated their declining R&D productivity. As a result, mega-mergers have delivered relatively flat sales growth, once the initial synergies were realized. Probable causes of this outcome include the complexities of managing larger scale organizations, integrating R&D sites from organizations entrenched in different cultures, and growing over-diversified portfolios of products. In short, regardless of its scale, consolidation proved to be a double-edged sword. It can fill organic productivity gaps while rendering these same R&D organizations too big and too complex to effectively deliver innovation. Consolidation cannot therefore provide a single, lasting solution to the growth challenge of large pharmas. Tapping Into Adjacent Segments The prospects for growth in pharmaceuticals may be confined. Large pharmas had a combined revenue base of about $35 billion in 211, excluding revenues from non-pharmaceutical businesses. Growing this revenue base at recent industry growth rate and offsetting the revenue cliff from loss of exclusivity would result in an incremental revenue need of $15 billion for the group by 216. Considering the overall industry is expected to grow by $22-25 billion during the same period, according to IMS, large pharmas may consider expanding the boundaries of the market in which they search for growth. Diversifying into health care adjacencies is not a new idea and has taken place at different points of life for large pharmas. Companies such as Johnson & Johnson and Abbott Laboratories Inc. a long time ago built their foundations on diversified businesses. Their goal was to balance the R&D and regulatory risk of their pharmaceutical operations with more predictable businesses. More recently, spurred on by macroeconomic woes and a renewed emphasis on delivering an integrated approach to patient care through a diversified portfolio of complementary products and services, companies such as Novartis, Sanofi, and Daiichi Sankyo Co. Ltd. have followed the same path by expanding into adjacencies like generics, consumer products, and devices. This strategy may suffer, however, from an economic flaw in the fundamental difference of operating margins and profitability across health care segments. Branded drugs remain the largest and most profitable health care segment, with operating margins in the 2%-3% range. Adjacencies such as generics or diagnostics offer smaller and less profitable opportunities for addressing the shortcoming of large pharma scale. Generics for example are today a global market of about $2 billion with smaller profit due to lower margins in the range of 15-2%. Certainly, large pharmas can address some of their growth Exhibit 5 Mid-Tier Pharmas (21-211) Number Of Companies SOURCE: L.E.K. Consulting Acquired Mid-Tier Mid-Tier Pharma gap by broadening the horizon of health care segments in which they participate. However, diversification alone falls short of addressing large pharma bottom line. Rescaling The Base Facing the limited prospects of consolidation and diversification, large pharmas must turn their attention to rescaling their revenue bases through deconsolidation or scale realignment along key areas of competitive advantage. This is the industry s key structural issue. Rescaling the base would enable some large pharmas to focus on a smaller core of products, services, and customers. This strategy can first take place through deconvergence of diversified businesses across health care segments. Abbott s recent decision to split its innovative pharmaceutical business from its diagnostic, device, nutrition, and established products divisions calls for realizing the true value of its individual assets. The company will split into AbbVie Inc., an innovative pharma business that will continue to market pharmaceuticals, and Abbott, which will continue to focus on generics, devices, and diagnostics. Or consider BMS decision to refocus on biopharmaceuticals, selling its Convatec wound care unit, its North American OTC business, its medical imaging group, and its nutritional business Mead Johnson Nutrition Co. Pfizer has recently embarked on a similar path, with divestments of its animal health and nutritionals businesses. Other industries have successfully rescaled their operations to address their New Mid-Tier 212 Windhover Information Inc., an Elsevier company IN VIVO: The Business & Medicine Report December 212 5
6 Exhibit 6 Leadership Position Of Large Pharmas In Major Therapeutic Areas (216) Oncology / Hematology Antibacterials, Antivirals, Vaccines Share of Global Brand Sales (217) Pfizer 18% 13% Johnson & Johnson Novartis Merck Roche Sanofi Glaxo Smith Kline Abbott Astra Zeneca Lilly Rheumatology 9% Diabetes 9% Cardiology 8% Respiratory 7% CNS 4% Multiple Sclerosis 3% HBV/HCV 3% Orphan Diseases 3% Therapeutic area leader Top tier leader Second tier leader No leadership Therapeutic area leader = largest market share by 217; Top tier leader = second or third largest market share by 217; Second tier leader = fourth to seventh market share by 217; and No leadership = No market presence or market share behind seventh. SOURCE: Cowen Biotech Research Team and Cowen Pharmaceuticals Research Team; L.E.K. Consulting growth challenges. Large media and telecommunications companies such as Disney, Time Warner Inc., and Viacom Inc. have recently adopted, after years of consolidation and convergence, a strategy of refocusing on a few core businesses through divestitures and spin-offs of non-core assets. The emergence of new technologies and new competitors were a major trigger for deconsolidation. But executives at those companies recognized the limitations of their companies scale and deployed rescaling strategies that reward long-term shareholder value creation over short-term bottom-line growth. It s unclear to what extent that realization has taken hold among the largest companies in biopharmaceuticals. Beyond deconvergence for large pharmas diversified across multiple health care segments, these companies may focus on redistributing resources and investments within their core pharmaceutical business in areas where they can displace established and emerging competitors by gaining the advantage of their scale within a focused area of expertise: for example, a core channel like hospital-based markets, a key customer segment like specialists, a predominant product type like biologics, or a set of key therapeutic areas like oncology and diabetes. Looking back at the five best performing companies of 211, four generated growth from their leadership position in a small base of therapeutic areas: Biogen Idec in multiple sclerosis, Celgene in oncology, Novo Nordisk in diabetes, and Shire in ADHD and human genetic therapies. In contrast, many large pharmas are over-diversified across diseases where they are underscaled and unfit for competing against market leaders. A close look at the expected leadership position of large pharmas in the 1 top disease areas by 216 highlights this uneven and asymmetrical portfolio distribution. (See Exhibit 6.) One solution for large pharmas is to refocus their disease coverage into fewer areas by divesting or risk-sharing subscaled therapeutic areas. GlaxoSmithKline PLC and Pfizer took this path in HIV by forming ViiV Healthcare joint venture in 29. AstraZeneca PLC and BMS, as well as Eli Lilly & Co. and Boehringer Ingelheim GMBH, are jointly building up their diabetes presences. Merck & Co. Inc. has repeatedly deployed this strategy, starting their joint venture in 1994 with Astra AB of Sweden in multiple therapeutic areas such as gastrointestinal and cardiovascular diseases and more recently the equally owned partnership with Schering-Plough in 2 to develop and market new prescription medicines for cholesterol. This scale-sharing model enables large pharmas to reinvest most of their R&D and commercial budgets in fewer therapeutic areas where they can build leadership while minimizing risks and investments in others by sharing assets, resources, and investments with peers. Choices for the Future This analysis suggests that large pharmas increase in scale and revenue base will become one of their major impediments to shareholder value creation. Fortunately, there are a number of steps executives can take. For some, leveraging scale to outperform competition in accessing external innovation and seizing the opportunities of high barrier-to-entry markets may remain a safe harbor until a renewed era of productivity and prosperity. But few large pharmas will win at this game. The majority should focus their efforts 6 December 212 IN VIVO: The Business & Medicine Report
7 on those therapeutic areas where leadership can be preserved or attained, while being more receptive to divesting or to risk-sharing arrangements for subscale franchises. Companies should design incentives, dedicate resources, and foster a culture of creativity that rewards innovative deal structures and risk-sharing collaborations that support the recalibration of their business around fewer areas of leadership. Meanwhile, the industry must continue to assess the real profit contribution of adjacent health care sectors outside branded pharmaceuticals and decide how much (if anything) to invest in businesses that do not clearly enhance the value of their core pharma businesses. Finally, large pharma must recognize the true productivity of their organic R&D as well as the landscape of external innovation in which they play. Only a sober assessment of the potential constraints of this supply of innovation and the competition for it will reveal portfolio gaps and provide insights into realistic growth targets and the limits of increased scale. [A# ] IV Pierre Jacquet, MD, PhD, and David Barrow are Vice Presidents and Matthias Kleinz is an engagement manager in the Life Science Practice of L.E.K. Consulting. Michael Gladstone is an analyst at Atlas Venture. the author: p.jacquet@lek.com RELATED READING The Value of Scale in Pharma s Future IN VIVO, September 21 [A#218177] Pharma R&D: Doing the Same Thing That Didn t Work Before IN VIVO, April 29 [A#29872] The New Face Of Blockbuster Drugs IN VIVO, May 211 [A#211874] Institutionalizing Externalization At Big Pharma The Third Leg IN VIVO, March 212 [A#212851] Access these articles at our online store Windhover Information Inc., an Elsevier company IN VIVO: The Business & Medicine Report December 212 7
8 L.E.K. Consulting L.E.K. Consulting is a global management consulting firm that uses deep industry expertise and analytical rigor to help clients solve their most critical business problems. Founded 3 years ago, L.E.K. employs more than 1, professionals in 21 offices across Europe, the Americas and Asia-Pacific. L.E.K. advises and supports global companies that are leaders in their industries including the largest private and public sector organizations, private equity firms and emerging entrepreneurial businesses. L.E.K. helps business leaders consistently make better decisions, deliver improved business performance and create greater shareholder returns. For more information, go to L.E.K. s Biopharmaceuticals and Life Sciences Expertise L.E.K. Consulting is a premier strategic advisor to the life sciences industry. Our clients include four of the top-five global biotech companies, nine of the top-1 global pharmaceutical companies, leading tools and diagnostics companies, and many of the most innovative emerging public and private companies in the industry. L.E.K. s team of international life sciences professionals has expertise across all major industry segments and therapeutic areas, and we provide support at each stage of the product life cycle, from drug discovery to post-launch. With a reputation for solving complex issues and helping clients to create lasting value, L.E.K. works closely with life science executives to guide strategic decision making and develop winning strategies in a dynamic global healthcare market. For more information, go to or lifesciences@lek.com.
Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset
Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened
More informationCHEM-E4140 Selectivity 12. Pharma Business
CHEM-E4140 Selectivity 12. Pharma Business Prof. Ari Koskinen Laboratory of Organic Chemistry C318 Pharma Business Total volume ca 1100 G$ (Shell 421G$; Walmart 486G$; Toyota 252 G$). Annually approx 25
More informationAnnual Press Conference 2012. Business Year 2011
Business Year 2011 Highlights of the Business Year 2011 Andreas Barner Chairman of the Board of Managing Directors Corporate Board Division Pharma Research, Development and Medicine Value through Innovation
More information5/5/2015 PHARMACY WHAT S AN EMPLOYER TO DO? Current Structure Misaligned
PHARMACY WHAT S AN EMPLOYER TO DO? MAY 15, 2015 Debbie Doolittle Nashville, TN Pharmaceutical Spending Per Capita, 2013 vs. 2018 The US vs. the Rest of the World 1 Current Pharmacy Landscape How Did We
More informationIn the largest and perhaps the most ambitious collaborative
FEATURES THE BIRTH OF TRANSCELERATE BIOPHARMA, INC. Revolution in Clinical Research Partnerships by Dalvir Gill and Garry Neil In the largest and perhaps the most ambitious collaborative effort ever initiated
More informationGlobal Peptide Therapeutics Market 2014-2018
Brochure More information from http://www.researchandmarkets.com/reports/3022209/ Global Peptide Therapeutics Market 2014-2018 Description: About Peptide Therapeutics Peptides are amino acids sequences
More informationTHE BIOTECH & PHARMACEUTICAL INDUSTRY
THE BIOTECH & PHARMACEUTICAL INDUSTRY ESSENTIAL CAREERS INFORMATION CALUM LECKIE KATIE BISARO CAREERS CONSULTANTS What we will cover Sector overview Types of role Graduate recruitment trends and issues
More informationCopyright 2009 SAS Institute Inc. All rights reserved. Success With Business Analytics in the New Pharmaceutical Commercial Model.
Copyright 2009 SAS Institute Inc. All rights reserved. Success With Business Analytics in the New Pharmaceutical Commercial Model. Emerging Commercial Models: Rethinking Analytics Deloitte Consulting LLP
More informationKeys to success in multi-channel marketing in Japan
Keys to success in multi-channel marketing in Japan Abstract In the US and Europe, we have seen a drastic decline in the number of MRs and a rapid shift towards non-traditional multi-channel marketing
More information2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q
2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationPharmaceutical Sales Compensation
Past, Present and Future With highlights from the Towers Watson/Synygy Survey of Strategic Sales Incentive Plan Design and Governance in the Pharmaceutical Industry By Elliot Scott Past, Present and Future
More information6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality
6 th Proactive GCP Compliance Effective Risk- Based Approaches for Optimizing Clinical Quality March 24-25, 2015 Wyndham Philadelphia Historic District, Philadelphia, PA www.exlevents.com/gcp Sponsors
More informationBusiness Development & Licensing Journal For the Pharmaceutical Licensing Groups
www.plg-uk.com Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Consolidation in the generics sector Integrating business development Cross-cultural negotiations Self-reporting
More informationPharma s Sharp Right Turn on R&D Creating an IT Platform to Fuel Future Growth
Accenture Life Sciences Rethink Reshape Restructure for better patient outcomes Pharma s Sharp Right Turn on R&D Creating an IT Platform to Fuel Future Growth Leading pharmaceutical companies are evaluating
More informationRichard T. Clark Chief Executive Officer and President. Executing on Our Strategy
Richard T. Clark Chief Executive Officer and President Executing on Our Strategy Merck s Plan to Win: Preparing for Our Future Success BECOME THE MOST TRUSTED INDUSTRY LEADER IN DELIVERING VALUE TO CUSTOMERS
More informationA Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field
A Private Investor Guide to Regenerative Medicine: Unique Opportunities in an Emerging Field Introduction The field of regenerative medicine remains at the forefront of personalized medicine and healthcare
More informationGlobal Pharmaceuticals Marketing Channel Reference EDITION
Global Pharmaceuticals Marketing Channel Reference EDITION 2015 ABOUT IMS HEALTH IMS Health is a leading global information and technology services company providing clients in the healthcare industry
More informationTHE MISSING LINKS IN INVESTMENT ANALYSIS A PORTFOLIO MANAGEMENT STRATEGY TO MAKE INVESTMENTS WORK
THE MISSING LINKS IN INVESTMENT ANALYSIS A PORTFOLIO MANAGEMENT STRATEGY TO MAKE INVESTMENTS WORK MICHAEL HEPINSTALL DANIEL LYONS MARK PELLERIN Confronted with tighter profit margins and greater risks,
More informationThe Missing Keys in Key Account Management: Three Questions That Can Transform Your Sales Force. Bill Coyle and Jude Konzelmann
The Missing Keys in Key Account Management: Three Questions That Can Transform Your Sales Force Bill Coyle and Jude Konzelmann The Missing Keys in Key Account Management: Three Questions That Can Transform
More informationThird-Quarter 2015 Earnings Conference Call Executive Commentary Highlights. October 27, 2015
Third-Quarter 2015 Earnings Conference Call Executive Commentary Highlights October 27, 2015 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA This presentation of Merck & Co., Inc.,
More information2013 ICT Enterprise Insights in the Life Sciences Industry
2013 ICT Enterprise Insights in the Life Sciences Industry Key findings from the 2013 survey results Reference Code: IT010-000185 Publication Date: 03 Oct 2013 Author: Andrew Brosnan SUMMARY Catalyst The
More informationOperations Excellence in Professional Services Firms
Operations Excellence in Professional Services Firms Published by KENNEDY KENNEDY Consulting Research Consulting Research & Advisory & Advisory Sponsored by Table of Contents Introduction... 3 Market Challenges
More informationNew Deals Are Moving from Scale to Strategic Value
Companies historically have viewed mergers and acquisitions as a way to spur growth by bulking up : adding scale and market share by combining with another organization offering similar or complementary
More informationThe Factors Fueling Rising Health Care Costs 2008
The Factors Fueling Rising Health Care Costs 2008 Prepared for America s Health Insurance Plans, December 2008 2008 America s Health Insurance Plans Table of Contents Executive Summary.............................................................2
More informationOrphan Pharma: pathfinders for an increasingly specialised industry
Orphan Pharma: pathfinders for an increasingly specialised industry Foreword We are continuing our series by profiling the R&D and Clinical Development leadership of European and North American specialty
More informationBEST PRACTICES RESEARCH
2013 Frost & Sullivan 1 We Accelerate Growth Entrepreneurial Company of the Year Award Pharmaceutical Knowledge Process Outsourcing North America, 2013 Frost & Sullivan s Global Research Platform Frost
More informationThe Rising Tide of Pharmacy Benefit Cost and Complexity: A health plans roadmap to optimizing pharmacy services relationships
The Rising Tide of Pharmacy Benefit Cost and Complexity: A health plans roadmap to optimizing pharmacy services relationships New pharmacy benefit challenges After several years of manageable pharmacy
More informationVirtual Detailing in Life Science Organizations
Healthcare Virtual Detailing in Life Science Organizations Table of Contents Problem Summary Pharmaceutical Life Science Product Sales The Deteriorating Dynamics Life Science Sales & Marketing: Between
More informationUnleashing your growth potential Product Innovation and Development
www.pwc.se Unleashing your growth potential Product Innovation and Development Delivering growth and profitability through innovative products and services Knowledge Innovation Unleashing potential PwC
More informationLife Sciences Outlook. New Jersey 2015
Life Sciences Outlook New Jersey 2015 New Jersey M&A activity in New Jersey has led to the consolidation of surplus real estate holdings and diminished head counts. However, midsized companies are helping
More informationThe Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals
The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical
More informationLABORATORY OUTSOURCING
June 2009 LABORATORY OUTSOURCING Intertek s EVP of Analytical Services, Dr. Andrew Swift, discusses laboratory outsourcing and explains how dedicated analytical service providers are stepping up to support
More informationSage ERP I White Paper
The Premier Provider of Effective Business Software Solutions National Presence, Local Touch 1.800.4.BLYTHE www.blytheco.com I White Paper Proactive Regulatory Compliance for Biopharmaceutical Global Competitiveness
More informationWhat Lies Ahead? Trends to Watch: Health Care Product Development in North America
What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the
More informationDecember 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES
December 17, 2014 HOW PHARMA MARKETERS FIND AND SELECT DIGITAL MARKETING AGENCIES by Dennis van Rooij with Tim van Tongeren EXECUTIVE SUMMARY More than half of pharma marketers don t or can t leverage
More informationThe Top 10 Contract Research Organizations
OUTSOURCING The Top 10 Contract Research Organizations Positioning, performance and SWOT analyses Table of Contents Copyright 2009 Business Insights Ltd This Management Report is published by Business
More informationThe future of M&A in telecom
The future of M&A in telecom McKinsey & Company s analysis of past telecom mergers and acquisitions provides new insights into where the industry is likely headed. By Jean-Christophe Lebraud and Peter
More informationCegedim Half-year results 2009 September 2009
Cegedim Half-year results 2009 September 2009 1 Cegedim : Healthcare - its primary market Cegedim Founded in 1969 by Jean-Claude Labrune Jean-Claude Labrune family hold 67 % of Cegedim through FCB 849
More informationA Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market
A Product and Pipeline Analysis of the Multiple Sclerosis Therapeutics Market Launch of Several Pipeline Oral Products Could Diminish the Market for Injectable Therapies NEC3-52 November 2014 Contents
More informationOpen Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum
Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities
More informationMSD Information Technology Global Innovation Center. Digitization and Health Information Transparency
MSD Information Technology Global Innovation Center Digitization and Health Information Transparency 10 February 2014 1 We are seeking energetic, forward thinking graduates to join our Information Technology
More informationCreative financing: Private equity in life sciences
: Private equity in life sciences The Colonnade Hotel, Boston, MA October 28, 2008 Industry trends and implications 2 Setting the Stage Overall trends Aging population Emerging market opportunities - access
More informationshutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success
shutterstock.com Interim Management and Strategic Transactions for International Life Science Companies TCG: experienced, connected, proven success Proven success and contacts. Not just talk. TCG is a
More informationHRG. HRG Insight: Making Successful Sourcing Decisions. Harvard Research Group Experience - Expertise - Insight - Results
HRG Harvard Research Group HRG Insight: Making Successful Sourcing Decisions Harvard Research Group recommends that organizations include sourcing decision-making as part of their ongoing strategic planning.
More informationMatthew Emmens CEO Shire plc
Goldman Sachs 28 th Annual Global Healthcare Conference June 13, 2007 Matthew Emmens CEO Shire plc THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included
More informationSage ERP I White Paper
The Premier Provider of Effective Business Software Solutions National Presence, Local Touch 1.800.4.BLYTHE www.blytheco.com I White Paper Profitable Innovation Medical Device Business Model for Growth
More informationGreat Expectations: Why Pharma Companies Can t Ignore Patient Services
Accenture Life Sciences Rethink Reshape Restructure... for better patient outcomes Great Expectations: Why Pharma Companies Can t Ignore Patient Services Accenture Research Note: Key findings from a survey
More informationPharma working capital performance highly variable
April 2014 Pharma working capital performance highly variable 41 Billion in Excess Working Capital We last completed this survey in 2012. We expected that there would be a broad improvement across the
More informationTABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...
CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and
More informationRoss Career Services. Health Care. Introduction. Health Care Overview
Ross Career Services Career Path: Health Care Introduction Ross Career Services (RCS) created the Career Path series to assist students with the career search process. Each Career Path (online) handout
More informationCreating Joint Value. In Biopharma and Many Other Industries, Not Invented Here Is SO Last Century. By Ben Gomes-Casseres
Creating Joint Value In Biopharma and Many Other Industries, Not Invented Here Is SO Last Century By Ben Gomes-Casseres 36 STRATEGIC ALLIANCE MAGAZINE Q3 2014 Look at any of your alliances. How do you
More informationThe changing face of technology buyers
The changing face of technology buyers As executives beyond IT buy more technology and influence IT s purchasing decisions, technology companies need to learn how to sell to these new buyers. By Mark Brinda
More informationThe Business Case for Using Big Data in Healthcare
SAP Thought Leadership Paper Healthcare and Big Data The Business Case for Using Big Data in Healthcare Exploring How Big Data and Analytics Can Help You Achieve Quality, Value-Based Care Table of Contents
More informationGlobal Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
Brochure More information from http://www.researchandmarkets.com/reports/3453273/ Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019 Description: About non-small cell lung cancer therapeutics
More informationTIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials
TIBCO Spotfire Helps Organon Bridge the Data Gap Between Basic Research and Clinical Trials Pharmaceutical leader deploys TIBCO Spotfire enterprise analytics platform across its drug discovery organization
More informationMedTech Outsourcing: Is the Past Any Indication of the Future?
MedTech Outsourcing: Is the Past Any Indication of the Future? Timothy Blair, Director, Global Business Development, NAMSA Strategic Perspective NAMSA Whitepaper #11 10/2014 MedTech Outsourcing: Is the
More informationEnterprise Performance Management in the Pharmaceutical Industry. kpmg.co.uk
Enterprise Performance Management in the Pharmaceutical Industry kpmg.co.uk Are your performance management processes, metrics and tools prepared for tomorrow s strategic challenges in pharmaceuticals?
More informationThe Role of Regional Medical Advisor (RMA)-Field Medical. Dr. Aju Abraham Varghese Pfizer India. Feb 22 nd 2014
The Role of Regional Medical Advisor (RMA)-Field Medical Dr. Aju Abraham Varghese Pfizer India Feb 22 nd 2014 Disclaimer The opinions expressed in this presentation are solely those of the presenter and
More informationSolution Overview Channel Management in Utilities
Utilities Sector Solution Overview Channel Management in Utilities Better Results Market Influences and Challenges The utilties industry has faced dramatic change and numerous challenges in recent years
More informationHealthcare, Regulatory and Reimbursement Landscape - Australia
Brochure More information from http://www.researchandmarkets.com/reports/2207850/ Healthcare, Regulatory and Reimbursement Landscape - Australia Description: Healthcare, Regulatory and Reimbursement Landscape
More informationValue Creation through Business Innovation in the Pharmaceutical and Medical Technology Sector
Value Creation through Business Innovation in the Pharmaceutical and Medical Technology Sector Fred Nijland Annemarie van Hoogstraten Nanning de Jong 1 Summary The Dutch market for the pharmaceutical and
More informationIntegrated Life Cycle Patient Access Solutions that Maximize Brand ROI
Integrated Life Cycle Patient Access Solutions that Maximize Brand ROI August, 2013 Bob Hastings Vice President of Marketing Pharmaceutical brand marketers are facing a paradigm shift in the way they market
More informationSAY NEW INVESTOR DEMANDS ARE RESHAPING THE COMPETiTIVE LANDSCAPE. Frontline Revolution: The New Battleground for Asset Managers
Frontline Revolution: The New Battleground for Asset Managers Asset managers are rethinking their business models to capitalize on new trends in investor demand, according to a State Street survey of 300
More informationThe Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion
November 2013 Edition Vol. 7, Issue 10 The Evolving Landscape of Payment Care Delivery and Manufacturer Implications of Coverage Expansion By Gordon Gochenauer, Director, Oncology Commercial Strategies,
More informationAcquisition of. Special Investor Presentation
Acquisition of Special Investor Presentation October 21, 2015 Forward-looking Statements This presentation contains statements which constitute forward-looking statements within the meaning of Section
More informationCOGENT CONSULTING, INC.
COGENT CONSULTING, INC. point of view Taking the Guesswork out of Resource Allocation How to align marketing investments with growth opportunities and potential Doing More with Less The Patent Cliff. The
More informationBiomedical Business: Current Trends, Product Challenges and Future Outlook
Biomedical Business: Current Trends, Product Challenges and Future Outlook Prepared and Presented by Audrey S. Erbes, Ph.D. Principal, Erbes & Associates Life Science Marketing and Business Development
More informationMEDICAL DEVICE & DIAGNOSTICS
to Guide Strategic Medical Device and Introduction Medical device and diagnostic makers face myriad challenges when developing a new product, including working within resource and financial constraints,
More informationCUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT. EXECUTIVE SUMMARY April 2013
CUSTOMER ATTAINMENT FROM EVENT ENGAGEMENT EXECUTIVE SUMMARY April 2013 Copyright CMO Council. All Rights Reserved. 2013 ABSTRACT Change and transformation have become common occurrences if not required
More informationHealthcare Innovation in the UK - A Royal Society of Chemistry Position Paper
Healthcare Innovation in the UK - A Royal Society of Chemistry Position Paper Introduction The pharmaceutical industry (Pharma) has made important contributions to quality of life, longevity, economic
More informationMultiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013
Multiple Sclerosis Current and Future Players GDHC1009FPR/ Published March 2013 Executive Summary Moderate Growth in the Multiple Sclerosis Market is Expected from 2012 2022 GlobalData estimates the 2012
More informationAPAC CRO Market A deep dive into the trends transforming APAC CRO industry. P86A-52 June 2015
APAC CRO Market A deep dive into the trends transforming APAC CRO industry June 2015 Table of Contents Section Slide Numbers Executive Summary 10 Key Findings 11 Total CRO Market Size By Stages of Clinical
More informationKNOWLEDGENT WHITE PAPER. Big Data Enabling Better Pharmacovigilance
Big Data Enabling Better Pharmacovigilance INTRODUCTION Biopharmaceutical companies are seeing a surge in the amount of data generated and made available to identify better targets, better design clinical
More informationThe Future of Consumer Health Care
The Future of Consumer Health Care Coming Together To Lead The Consumer Health Care Industry 2 Creating a New Business Model in Consumer Health Care 3 Serve More Consumers In More Parts of the World, More
More informationProduct Life Cycle Management in Life Sciences Industry
Life Cycle Management in Life Sciences Industry Evolving from siloed to cross-functional management Audit. Tax. Consulting. Corporate Finance. A need for Lifecycle Management Life Sciences companies are
More informationT r a n s f o r m i ng Manufacturing w ith the I n t e r n e t o f Things
M A R K E T S P O T L I G H T T r a n s f o r m i ng Manufacturing w ith the I n t e r n e t o f Things May 2015 Adapted from Perspective: The Internet of Things Gains Momentum in Manufacturing in 2015,
More informationKey Findings. Use this report to... The Autoimmune Market Outlook to 2013
Key Findings The global autoimmune market generated sales of $31.9bn in, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.
More informationTHE SUSTAINABLE WAY TO GROW
Financial Services POINT OF VIEW THE SUSTAINABLE WAY TO GROW WHAT WEALTH MANAGERS CAN LEARN FROM OTHER PROFESSIONAL SERVICES AUTHOR Philippe Bongrand, Partner Wealth Management is a professional services
More informationJOHN REID PhD, MBA. (302) 544-1743 entrepidbd@gmail.com http://www.linkedin.com/in/jdreid1
JOHN REID PhD, MBA (302) 544-1743 entrepidbd@gmail.com http://www.linkedin.com/in/jdreid1 PROFILE Senior-level business development and licensing executive with a well-honed ability to translate scientific
More informationHow To Understand And Understand Biosimilars
Welcome to Biosimilars 20/20, presented by the Specialty Pharma Education Center (SPEC) in partnership with the Specialty Pharma Journal (SPJ). Please note that this is a preliminary agenda that is subject
More informationSAMPLE. Asia-Pacific Interventional Cardiology Procedures Outlook to 2020. Reference Code: GDMECR0061PDB. Publication Date: May 2014
Asia-Pacific Interventional Cardiology Procedures Outlook to 2020 Reference Code: GDMECR0061PDB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationPERFORMANCE-BASED EQUITY PRACTICES WITHIN LARGE BIOPHARMA
PERFORMANCE-BASED EQUITY PRACTICES WITHIN LARGE BIOPHARMA By Ed Speidel, Senior Vice President and Rob Surdel, Assistant Vice President Whether owed to regulatory and investor pressure, or simply a reflection
More informationTopic: IT Application Outsourcing (AO) in the Healthcare Payer Industry
Topic: IT Application Outsourcing (AO) in the Healthcare Payer Industry Healthcare Outsourcing Annual Report: July 2012 Preview Deck Our research offerings for global services Subscription information
More informationPERSPECTIVE Drug Discovery Today Volume 17, Numbers 13/14 July 2012
drug development: an economically viable strategy for biopharma R&D feature Kiran N. Meekings 1, kiran.meekings@thomsonreuters.com, Cory S.M. Williams 2 and John E. Arrowsmith 1 drug incentives have stimulated
More informationAisling Capital IV, LP
Venture Capital Fund Commitment Aisling Capital IV, LP August 5, 2015 See Last Page for Disclaimer Luke M. Jacobs, Portfolio Manager, Private Markets Overview Aisling Capital IV, LP Venture Capital Fund
More informationInnovations in Pharma Sales Operations
Innovations in Pharma Sales Operations Sales Ops Importance in Pharma Pharmaceutical organizations are going through fundamental restructuring. They are facing changing regulations, intense cost pressure,
More informationJoin our scientific talent community
Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into
More informationFour Steps to Optimizing Trade Promotion Effectiveness. Figure 1. L.E.K. s Four-Step Framework for Improving Trade Promotion Programs STEP 3
Volume XIII, Issue 5 Four Steps to Optimizing Trade Promotion Effectiveness Trade promotion programs are pivotal to driving sales, building brand equity with consumers and strengthening channel partnerships.
More informationHealthcare Reform Opens Up Middle-Market Opportunities
WWW.IBISWORLD.COM April 2013 1 April 2013 By IBISWorld Analysts Douglas Kelly & Anna Son A changing healthcare landscape and increasing demand are spurring potential deal opportunities in related industries.
More informationPfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off?
Pfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off? Research February 6, 2012 Rusty Jones Companies: Pfizer (PFE) Ranbaxy (OTC: RBXZF) Watson (WPI) Products: Lipitor
More informationIDC MarketScape Excerpt: Worldwide Life Science R&D Strategic Consulting Services 2014 Vendor Assessment
IDC MarketScape IDC MarketScape Excerpt: Worldwide Life Science R&D Strategic Consulting Services 2014 Vendor Assessment Alan S. Louie, Ph.D. THIS IDC MARKETSCAPE EXCERPT FEATURES: ACCENTURE IDC MARKETSCAPE
More informationHow To Get A Better At Developing An Application
Whitepaper Rethink application possibilities and align to desired business outcomes EALA results January 2014 2014 Avanade Inc. All rights reserved. Executive summary It s a new world of applications.
More informationThe Procurement Value. and the key challenges to efficient execution
The Procurement Value IN LIFE SCIENCE and the key challenges to efficient execution Table of Contents Executive summary 3 1 Procurement: Untapped value for Pharmaceutical companies 4 2 Three main challenges
More informationScott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry
Scott Byrne & Rachel Weeks G400: Pharma Report 10/22/09 Direct to Consumer Advertising: The Affect on the Pharmaceutical Industry A Glance at the Pharmaceutical Industry The pharmaceutical industry is
More informationAccenture Risk Management. Industry Report. Life Sciences
Accenture Risk Management Industry Report Life Sciences Risk management as a source of competitive advantage and high performance in the life sciences industry Risk management that enables long-term competitive
More informationProblems Facing the Pharmaceutical Industry and Approaches to Ensure Long Term Viability
University of Pennsylvania ScholarlyCommons Master of Science in Organizational Dynamics Theses Organizational Dynamics Programs 5-4-2010 Problems Facing the Pharmaceutical Industry and Approaches to Ensure
More informationDigital Leaders Deal With a Range of Organizational Challenges
May 22, 2014 OVERCOMING OBSTACLES TO DIGITAL TRANSFORMATION SUCCESS IN THE PHARMACEUTICAL INDUSTRY Digital Leaders Deal With a Range of Organizational Challenges by Tim van Tongeren with Dennis van Rooij
More informationPharmaceutical forecasts address critical business questions for all
S A L ES & M A R K E TI NG I N SIGHTS Understanding Your Brand s Performance: Creating Robust Forecasts by Integrating Commercial and Clinical Drivers Art Cook, Nisha Gilra and Eric Persoff Pharmaceutical
More informationMalignant Pleural Mesothelioma - Pipeline Review, H2 2014
Brochure More information from http://www.researchandmarkets.com/reports/2904677/ Malignant Pleural Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Pleural Mesothelioma - Pipeline Review,
More informationPharmaceutical sales in Canada have a 2.5 percent share of the global market, making th
Industry Canada (/eic/site/icgc.nsf/eng/home) Home Industries and Business Canadian Life Science Industries Biopharmaceuticals and pharmaceuticals Pharmaceutical industry profile Life Science Industries
More information